Until recently, 340B program policy was largely debated in Washington, D.C. But as Congress remains stalemated on drug pricing, state capitols have suddenly leapt to the forefront. In this month’s column, I reflect on the … [Read more...]
News & Commentary
Pro 340B Grassroots Organization Gains Momentum
December 21, 2019 by
One of the biggest challenges the 340B community has faced over the years is a lack of program knowledge at a local level. As I reported in my May column, Community Voices for 340B (CV340B) is the first grassroots organization solely … [Read more...]
More States Embrace 340B Program as a Win-Win for Taxpayers, Patients and the General Public
November 23, 2019 by
Since I started my column earlier this year, I have written a number of pieces on the unprecedented attention that the 340B program is facing in state capitols. One of the more exciting developments is the growing interest among states to partner … [Read more...]
AIR340B Quietly Steps Up Advocacy Efforts
October 16, 2019 by
For those who have been involved in 340B advocacy for a while, you will likely have heard of AIR340B. The Alliance for Integrity and Reform of 340B (AIR340B) was launched by the pharmaceutical industry in 2013. Its members include the trade … [Read more...]
Recent 340B Developments of Interest and Words of Advice
September 12, 2019 by
Congress just returned to Washington, but there have been several 340B developments both in D.C. and in the states during the long summer recess. In my latest monthly column, I cover a few of these topics: 1) HRSA Solicits Bids … [Read more...]
Key Takeaways from the 340B Coalition Summer Conference
August 8, 2019 by
The 340B Coalition, the umbrella group for the 13 national trade associations that represent the providers participating in the 340B drug discount program, held its annual meeting July 15-17 in Washington, D.C. In this month’s column, I will share … [Read more...]
Hospital specialty pharmacies offer a solution to growing problems: medication access & affordability
August 8, 2019 by
Over the past year, I have learned a lot about specialty pharmacy and its importance to 340B providers and patients. A staggering 65% of the new drugs that came to market in 2018 were specialty drugs. These therapies can improve care and … [Read more...]
President’s Proposal to Require Drug Manufacturers to Disclose Prices in TV Ads
August 7, 2019 by
Ted Slafsky of Wexford Solutions Is Interviewed by Fox News Radio's daily podcast on the President's Proposal to Require Drug Manufacturers to Disclose Prices in TV Ads … [Read more...]
The View From the Nation’s Capital
July 1, 2019 by
This month’s column covers: 1) the significant uptick in drug manufacturer notices of overcharges to 340B providers and the importance of monitoring these developments. (2) The untold story of a little-known individual who played a … [Read more...]
A Welcome Addition to the 340B Debate
May 29, 2019 by
The pharmaceutical industry has successfully harnessed the power of patient groups to help in their advocacy efforts throughout state capitals and in Washington, D.C. According to the most recent data available, drug companies and their trade groups … [Read more...]